pemetrexed wh (pemetrexed synthon) innrennslisþykkni, lausn 25 mg/ml
williams & halls ehf. - pemetrexedum inn - innrennslisþykkni, lausn - 25 mg/ml
cinveron stungulyf, lausn 2 mg/ml
williams & halls ehf - ondansetronum hýdróklóríð - stungulyf, lausn - 2 mg/ml
dengvaxia
sanofi pasteur - chimeric yellow fever dengue virus serotype 1 (live, attenuated), chimeric yellow fever dengue virus serotype 2 (live, attenuated), chimeric yellow fever dengue virus serotype 3 (live, attenuated), chimeric yellow fever dengue virus serotype 4 (live, attenuated) - fjölmörgum - bóluefni - dengvaxia is indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4 in individuals 6 to 45 years of age with test-confirmed previous dengue infection (see sections 4. 2, 4. 4 og 4. notkun dengvaxia ætti að vera í samræmi við opinbera tillögur.
cloxabix hart hylki 100 mg
williams & halls ehf - celecoxibum inn - hart hylki - 100 mg
cloxabix hart hylki 200 mg
williams & halls ehf - celecoxibum inn - hart hylki - 200 mg
dolorin junior endaþarmsstíll 125 mg
williams & halls ehf.* - paracetamolum inn - endaþarmsstíll - 125 mg
dolorin tafla 500 mg
williams & halls ehf - paracetamolum inn - tafla - 500 mg
bisbetol filmuhúðuð tafla 10 mg
williams & halls ehf. - bisoprololum fúmarat - filmuhúðuð tafla - 10 mg
bisbetol filmuhúðuð tafla 5 mg
williams & halls ehf. - bisoprololum fúmarat - filmuhúðuð tafla - 5 mg
broksil saft 6 mg/ml
williams & halls ehf.* - ambroxolum hýdróklóríð - saft - 6 mg/ml